Skip to main content
SpringerLink
Log in

Aberrant hypermethylation of RASSF2 in tumors and peripheral blood DNA as a biomarker for malignant progression and poor prognosis of esophageal squamous cell carcinoma

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

As a tumor suppressor gene, RAS-association domain family 2 (RASSF2) is inactivated by promoter hypermethylation in different tumor cell lines and primary tumors. However, the role of RASSF2 in esophageal squamous cell carcinoma (ESCC) has remained uninvestigated. The aims of this study were to determine the role and methylation status of RASSF2 in esophageal cancer cell lines, ESCC tissues and white blood cells, and to evaluate the potential prognostic role of RASSF2 in ESCC. In the present study, we found frequent silencing of RASSF2 and up-regulation of the gene by 5-Aza-dC treatment in esophageal cancer cell lines. Aberrant methylation of the CpG sites close to the transcription start site induced silencing of RASSF2 expression and in vitro methylation of RASSF2 led to a significant decrease in luciferase activity. The results were further verified in clinical specimens and aberrant methylation of the CpG sites close to the transcription start site of RASSF2 was found in ESCC tumor tissues and peripheral white blood cells. Furthermore, RASSF2 hypermethylation was associated with lower level of RASSF2 expression. ESCC patients in stage III and IV, with negative expression or hypermethylation of the CpG sites close to the transcription start of RASSF2 demonstrated poor patient survival. Taken together, our results suggest that RASSF2 may function as a tumor suppressor gene that is inactivated through hypermethylation of CpG sites close to the transcription start site in ESCC and its expression or methylation may have prognostic implications for ESCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Nagaraja V, Eslick GD (2014) Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis. J Gastrointest Oncol 5:67–76

    PubMed Central  CAS  PubMed  Google Scholar 

  2. Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G (2010) Esophageal cancer: an update. Int J Surg 8:417–422

    Article  CAS  PubMed  Google Scholar 

  3. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–241

    Article  PubMed  Google Scholar 

  4. Guohong Z, Min S, Duenmei W, Songnian H, Min L, Jinsong L, Hongbin L, Feng Z, Dongping T, Heling Y, Zhicai L, Shiyong L, Quansheng G, Xiaoyun L, Yuxia G (2010) Genetic heterogeneity of oesophageal cancer in high-incidence areas of southern and northern China. PLoS One 5:e9668

    Article  PubMed Central  PubMed  Google Scholar 

  5. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Dubrow R, Rotterdam H, West AB, Blaser M, Blot WJ, Gail MH, Fraumeni JF Jr (2003) Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 95:1404–1413

    Article  PubMed  Google Scholar 

  6. Spandidos DA, Sourvinos G, Tsatsanis C, Zafiropoulos A (2002) Normal ras genes: their onco-suppressor and pro-apoptotic functions. Int J Oncol 21:237–241

    CAS  PubMed  Google Scholar 

  7. Ponting CP, Benjamin DR (1996) A novel family of Ras-binding domains. Trends Biochem Sci 21:422–425

    Article  CAS  PubMed  Google Scholar 

  8. Donninger H, Vos MD, Clark GJ (2007) The RASSF1A tumor suppressor. J Cell Sci 120:3163–3172

    Article  CAS  PubMed  Google Scholar 

  9. Hesson L, Dallol A, Minna JD, Maher ER, Latif F (2003) NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 22:947–954

    Article  CAS  PubMed  Google Scholar 

  10. Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B (2009) Aberrant CpG Island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest 27:459–465

    Article  CAS  PubMed  Google Scholar 

  11. Guo W, Cui L, Wang C, Guo Y, Shen S, Kuang G, Dong Z (2014) Decreased expression of RASSF1A and up-regulation of RASSF1C is associated with esophageal squamous cell carcinoma. Clin Exp Metastasis 31:521–533

    Article  CAS  PubMed  Google Scholar 

  12. Han L, Dong Z, Wang C, Guo Y, Shen S, Kuang G, Guo W (2014) Decreased expression and aberrant methylation of RASSF5A correlates with malignant progression of gastric cardia adenocarcinoma. Mol Carcinog. doi:10.1002/mc.22245

    PubMed Central  Google Scholar 

  13. Guo W, Wang C, Guo Y, Shen S, Guo X, Kuang G, Dong Z (2015) RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma. Clin Exp Metastasis 32:83–98

    Article  CAS  PubMed  Google Scholar 

  14. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ (2003) RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 278:28045–28051

    Article  CAS  PubMed  Google Scholar 

  15. Song H, Oh S, Oh HJ, Lim DS (2010) Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity. Biochem Biophys Res Commun 391:969–973

    Article  CAS  PubMed  Google Scholar 

  16. Cooper WN, Hesson LB, Matallanas D, Dallol A, von Kriegsheim A, Ward R, Kolch W, Latif F (2009) RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 28:2988–2998

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Donninger H, Hesson L, Vos M, Beebe K, Gordon L, Sidransky D, Liu JW, Schlegel T, Payne S, Hartmann A, Latif F, Clark GJ (2010) The Ras effector RASSF2 controls the PAR-4 tumor suppressor. Mol Cell Biol 30:2608–2620

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Huang KH, Huang SF, Chen IH, Liao CT, Wang HM, Hsieh LL (2009) Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clin Cancer Res 15:4174–4180

    Article  CAS  PubMed  Google Scholar 

  19. Zhang Z, Sun D, Van do N, Tang A, Hu L, Huang G (2007) Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer 120:32–38

    Article  CAS  PubMed  Google Scholar 

  20. Kiss NB, Kogner P, Johnsen JI, Martinsson T, Larsson C, Geli J (2012) Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas. BMC Med Genet 13:83

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Hesson LB, Wilson R, Morton D, Adams C, Walker M, Maher ER, Latif F (2005) CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 24:3987–3994

    Article  CAS  PubMed  Google Scholar 

  22. Cooper WN, Dickinson RE, Dallol A, Grigorieva EV, Pavlova TV, Hesson LB, Bieche I, Broggini M, Maher ER, Zabarovsky ER, Clark GJ, Latif F (2008) Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene 27:1805–1811

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Wu Y, Zhang X, Lin L, Ma XP, Ma YC, Liu PS (2014) Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer. Asian Pac J Cancer Prev 15:1171–1176

    Article  PubMed  Google Scholar 

  24. Endoh M, Tamura G, Honda T, Homma N, Terashima M, Nishizuka S, Motoyama T (2005) RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer 93:1395–1399

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Maruyama R, Akino K, Toyota M, Suzuki H, Imai T, Ohe-Toyota M, Yamamoto E, Nojima M, Fujikane T, Sasaki Y, Yamashita T, Watanabe Y, Hiratsuka H, Hirata K, Itoh F, Imai K, Shinomura Y, Tokino T (2008) Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis 29:1312–1318

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH (2010) Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer 9:264

    Article  PubMed Central  PubMed  Google Scholar 

  27. Richter AM, Haag T, Walesch S, Herrmann-Trost P, Marsch WC, Kutzner H, Helmbold P, Dammann RH (2013) Aberrant promoter hypermethylation of RASSF family members in merkel cell carcinoma. Cancers (Basel) 5:1566–1576

    Article  Google Scholar 

  28. Park HW, Kang HC, Kim IJ, Jang SG, Kim K, Yoon HJ, Jeong SY, Park JG (2007) Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int J Cancer 120:7–12

    Article  CAS  PubMed  Google Scholar 

  29. Zhao L, Cui Q, Lu Z, Chen J (2012) Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features. Pancreas 41:206–211

    Article  CAS  PubMed  Google Scholar 

  30. Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ, Brenner H (2008) Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One 3:e2656

    Article  PubMed Central  PubMed  Google Scholar 

  31. Kaaks R, Stattin P, Villar S, Poetsch AR, Dossus L, Nieters A, Riboli E, Palmqvist R, Hallmans G, Plass C, Friesen MD (2009) Insulin-like growth factor-II methylation status in lymphocyte DNA and colon cancer risk in the Northern Sweden Health and Disease cohort. Cancer Res 69:5400–5405

    Article  CAS  PubMed  Google Scholar 

  32. Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S (2011) BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat 129:69–77

    Article  CAS  PubMed  Google Scholar 

  33. Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, Giles GG, Hopper JL, Dobrovic A (2011) Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) 4:23–33

    Article  CAS  Google Scholar 

  34. Kondo Y, Shen L, Issa JP (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23:206–215

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408

    Article  CAS  PubMed  Google Scholar 

  36. Sasaki M, Anast J, Bassett W, Kawakami T, Sakuragi N, Dahiya R (2003) Bisulfite conversion-specific and methylation-specific PCR: a sensitive technique for accurate evaluation of CpG methylation. Biochem Biophys Res Commun 309:305–309

    Article  CAS  PubMed  Google Scholar 

  37. Li LC, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18:1427–1431

    Article  CAS  PubMed  Google Scholar 

  38. Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd J, Caligiuri MA, Plass C (2005) Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 37:265–274

    Article  CAS  PubMed  Google Scholar 

  39. Umemoto M, Yokoyama Y, Sato S, Tsuchida S, Al-Mulla F, Saito Y (2001) Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer. Br J Cancer 85:1032–1036

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Luo D, Ye T, Li TQ, Tang P, Min SD, Zhao GF, Huang H, Chang J, Wang Y, Lv L, Lu ML, Zheng MY (2012) Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients. Exp Ther Med 3:391–396

    PubMed Central  PubMed  Google Scholar 

  41. Guerrero-Setas D, Pérez-Janices N, Blanco-Fernandez L, Ojer A, Cambra K, Berdasco M, Esteller M, Maria-Ruiz S, Torrea N, Guarch R (2013) RASSF2 hypermethylation is present and related to shorter survival in squamous cervical cancer. Mod Pathol 26:1111–1122

    Article  CAS  PubMed  Google Scholar 

  42. Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM (2011) DNA methylation in white blood cells: association with risk factors in epidemiologic studies. Epigenetics 6:828–837

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358:1118–1128

    Article  CAS  PubMed  Google Scholar 

  44. Gharanei S, Brini AT, Vaiyapuri S, Alholle A, Dallol A, Arrigoni E, Kishida T, Hiruma T, Avigad S, Grimer R, Maher ER, Latif F (2013) RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma. Epigenetics 8:893–898

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank the patients for taking part in this study. Supported by Grants from the National Natural Science Foundation (No. 81472335).

Author information

Authors and Affiliations

  1. Laboratory of Pathology, Hebei Cancer Institute, The Fourth Hospital of Hebei Medical University, Jiankang Road 12, Shijiazhuang, 050011, Hebei, China

    Wei Guo, Zhiming Dong, Jianli Cui, Yanli Guo, Supeng Shen, Xin Guo & Gang Kuang

Authors
  1. Wei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhiming Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianli Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yanli Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Supeng Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xin Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gang Kuang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhiming Dong.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 19 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, W., Dong, Z., Cui, J. et al. Aberrant hypermethylation of RASSF2 in tumors and peripheral blood DNA as a biomarker for malignant progression and poor prognosis of esophageal squamous cell carcinoma. Clin Exp Metastasis 33, 73–85 (2016). https://doi.org/10.1007/s10585-015-9759-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-015-9759-5

Keywords

Search

Navigation